Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.1429.

HUMA has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $6.00 target price on shares of Humacyte in a report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. UBS Group restated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Monday, January 5th.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Humacyte by 7.4% during the third quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock worth $13,085,000 after acquiring an additional 520,431 shares during the last quarter. CenterBook Partners LP boosted its stake in Humacyte by 141.1% in the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock worth $7,169,000 after purchasing an additional 2,007,743 shares in the last quarter. Geode Capital Management LLC boosted its stake in Humacyte by 33.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after purchasing an additional 738,142 shares in the last quarter. Marshall Wace LLP grew its position in Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after purchasing an additional 2,590,394 shares during the last quarter. Finally, Private Advisor Group LLC increased its stake in Humacyte by 2.6% during the 3rd quarter. Private Advisor Group LLC now owns 1,029,080 shares of the company’s stock valued at $1,791,000 after purchasing an additional 26,400 shares in the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Stock Up 14.3%

Humacyte stock opened at $1.12 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. The firm has a market cap of $209.74 million, a P/E ratio of -4.87 and a beta of 1.93. The business has a fifty day moving average of $1.16 and a two-hundred day moving average of $1.60. Humacyte has a twelve month low of $0.91 and a twelve month high of $4.85.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The company had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.92 million. On average, analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.